Antibody-Drug Conjugates in Breast Cancer: Strategies for Toxicity Management

Allison Butts, PharmD, BCOP, describes what antibody-drug conjugates are and explains the role in metastatic breast cancer treatment.

An overview of antibody-drug conjugate therapies available for patients with metastatic breast cancer and triple-negative breast cancer based on outcomes demonstrated in clinical trials.

Impressions regarding the management of a 62-year-old woman with HER2-postive breast cancer who received adjuvant T-DM1 treatment following neoadjuvant TCHP and has signs of residual disease.

The types of conversations that breast oncologists should have with their patients with breast cancer before initiating T-DM1, and recommendations for managing treatment-related adverse events.

Recommendations for starting a patient with HER2+ metastatic breast cancer on T-DXd after prior T-DM1 therapy.

Strategies used to help monitor and manage T-DXd treatment-related adverse events.

Komal Jhaveri, MD, FACP, provides rationale for treating a patient with triple-negative breast cancer with sacituzumab govitecan.

Strategies that can be used to mitigate and manage adverse events associated with sacituzumab govitecan therapy for triple-negative breast cancer.

An overview of novel antibody-drug conjugate therapies currently under investigation as presented at SABCS 2021.

Clinical pearls regarding ways to integrate antibody-drug conjugates into treatment algorithms when managing patients with breast cancer.